Cytotoxic Drug Exposure Monitoring in HealthcareSydney

Category 1 offences carry penalties up to $10.4 million for corporations.

SafeWork NSW identifies healthcare and social assistance as a regulatory priority for 2025-26.

20 new psychosocial hazard inspectors deployed across the healthcare sector.

Reconstitution and dilution of cytotoxic drugs in safety cabinets generates aerosols and surface contamination. Cabinet performance must be verified through air monitoring and surface wipe sampling. Biological safety cabinet containment failures, damaged gloves, and improper technique during drug preparation are the primary sources of worker exposure in compounding settings.

Nurses and medical staff administering IV cytotoxic drugs face splash and aerosol exposure, particularly during connection and disconnection of infusion lines. Priming IV lines, clearing air bubbles, and managing drug spills during administration create opportunities for dermal and inhalation exposure. Surface contamination on infusion poles, bed rails, and treatment chairs is a secondary exposure pathway.

Hospital services staff handling contaminated linen, waste, and bodily fluids from patients treated with cytotoxic drugs face dermal and inhalation exposure. Cytotoxic drugs and their metabolites are excreted in urine, faeces, and other bodily fluids for up to 48 hours after treatment. Cleaning staff in treatment areas and bathrooms are exposed during routine cleaning.

Cytotoxic drugs contaminate surfaces during transport, preparation, and administration. Surface wipe sampling quantifies contamination levels on benchtops, floors, drug vial exteriors, and equipment. Studies consistently show measurable cytotoxic contamination on surfaces in treatment areas, even in facilities with robust handling protocols.

Typical Worker Groups

Common similar exposure groups (SEGs) assessed for this sub-category.

Regulatory Context

The National Standard for the Safe Handling of Cytotoxic Drugs in the Workplace requires containment verification through environmental monitoring. Cytotoxic drug handling is classified as requiring elimination or minimisation of exposure — there is no safe level. Biological safety cabinets used for compounding must comply with AS 2252.2 and be certified annually. The WHS Regulations require PCBUs to ensure that exposure to hazardous chemicals is eliminated or minimised so far as is reasonably practicable. Health surveillance for cytotoxic-exposed workers should include baseline and periodic health assessments.